Rapid Communication
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 14, 2006; 12(34): 5554-5556
Published online Sep 14, 2006. doi: 10.3748/wjg.v12.i34.5554
Table 1 Demographic, clinical, biochemical and molecular profiles of patients (mean ± SD, n = 28)
Demographic profile
M/F25:3
Age (yr)47.5 ± 13.2
Body weight (kg)60.6 ± 9.18
Clinical profile
Chronic hepatitis C (n)15
Compensated cirrhosis (n)13
ALT ( > 40 IU/L)18
ALT (< 40 IU/L)10
Molecular profile
Genotype 3 (n)21
Genotype 2 (n)5
Genotype 1 (n)2
Follow-up (mo)18.1 ± 6.7
Table 2 Response of therapy with respect to dose and genotype
Patients(n = 28)Response topeginterferon alpha 2bDose 50 mcg (n = 14)Response topeginterferon alpha 2bDose 80 mcg (n = 12)1
YesNoYesNo
Genotype 1 (n = 2)-11-
Genotype 2 (n = 5)3-2-
Genotype 3 (n = 21)8281